Zweig-DiMenna Associates’s AstraZeneca AZN Stock Holding History

Zweig-DiMenna Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,900	Closed	-$253K	–	250
2014 Q1	$253K	Sell	3,900 -1,200	-24%	-$77.5K	0.01%	159
2013 Q4	$303K	Buy	+5,100	New	+$277K	0.01%	151
2013 Q3	–	Sell	-7,357	Closed	-$348K	–	234
2013 Q2	$348K	Buy	+7,357	New	+$375K	0.01%	178

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Zweig-DiMenna Associates's AZN Position: Q2 2014 in Review

Zweig-DiMenna Associates sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 3,900 shares — an estimated $253K sold.

Zweig-DiMenna Associates first reported a position in AZN in Q2 2013 and held it in 3 quarters. The position peaked at $348K in Q2 2013. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Zweig-DiMenna Associates reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Zweig-DiMenna Associates sold 3,900 AstraZeneca shares in Q2 2014, an estimated $253K.
Zweig-DiMenna Associates first reported a position in AstraZeneca in Q2 2013 and held it in 3 quarters.
Zweig-DiMenna Associates's AstraZeneca position peaked at $348K in Q2 2013.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2014, filed 12 Aug 2014.